Navigation Links
Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease
Date:5/15/2009

nt of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Patients who develop a new infection during treatment with CIMZIA should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for immunocompromised patients, and appropriate antimicrobial therapy should be initiated. Appropriate empiric antifungal therapy should also be considered while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are endemic.

During controlled and open-labeled portions of CIMZIA studies of Crohn's disease and other diseases , malignancies (excluding non-melanoma skin cancer) were observed at a rate (95% confidence interval) of 0.5 (0.4, 0.7 ) per 100 patient-years among 4,650 CIMZIA-treated patients versus a rate of 0.6 (0.2, 1.7) per 100 patient-years among 1,319 placebo-treated patients. The size of the control group and limited duration of the controlled portions of the studies preclude the ability to draw firm conclusions. In studies of CIMZIA for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is approximately 2-fold higher than expected in the general population. Patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known.

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA has not been formally studied in patients
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
2. UCBs CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
3. Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohns Patients
4. UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. New Online Project Management Fundamentals for Healthcare Module Available
7. KT Tape: Secret Weapon of Elite Athletes - Now Available to Everyone
8. Fiber Technology Products that Help Combat Spread of Superbugs Now Available to the Consumer Market
9. Providence Service Corporation Makes Its Spring 2009 Presentation Publicly Available
10. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
11. Diatherix Laboratories Releases First Clinically Available Test For Confirmation of The Swine Flu Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... for people to comfortably hold a tablet while reducing the likelihood of it dropping. ...
(Date:9/2/2015)... ... September 02, 2015 , ... Available ... marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , an evolution ... biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing and moisturizing. ...
(Date:9/2/2015)... ... , ... The payroll conference theme this year is "TAKING ... legislative updates, including unemployment, global payroll best practices, and the latest trends in ... the American Payroll Association, Barnett Associates, and the IRS, will keep payroll professionals ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in 2007 ... and education, and helping fund more research remains our top priority,” commented Christine ...
(Date:9/2/2015)... ... ... Pentec Health, Inc., a national leader in outsourced pharmacy services, has been ... Less than 5 % of this year’s 5000 honorees share the “six-time” recognition; Pentec ... revenue growth rate of 65% sustained its most recent achievement. As an Inc. 5000 ...
Breaking Medicine News(10 mins):Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... UPMC Health Plan announced the,launch of a small ... small businesses -- UPMC Health Plan,s Small Business ... with 2 to 99,employees a high- quality, easy-to-implement ... tools, and a,dedicated account manager and customer service ...
... shows no link , THURSDAY, Oct. 18 (HealthDay News) -- ... or after exercise will not prevent muscle soreness, a new ... each involving from 10 to 30 people. , Nine of ... and the time spent stretching by participants varied from 40 ...
... and,Reported Diluted Earnings per Share Decreased 1% to $0.84. Diluted Earnings ... 2007 First Nine Months Worldwide Net Revenue Increased 10% to $16.6, ... Share, Before Certain Significant Items, Increased 10% ... to ...
... MITI ), a biopharmaceutical company focusing on ... treatment of cancer,inflammatory and autoimmune diseases, announced today ... Product Dossier (IMPD),for the conduct of a phase ... lymphoblastic leukemia (ALL) in Germany. MT103, a BiTE(R) ...
... 2,200-plus healthcare professionals and exhibitors registered for the,first-ever ... CHICAGO, Oct. 17 With studies from ... of students and,adults enrolling in distance education in ... Information and Management Systems Society (HIMSS),will host its ...
... Our ... Telemedicine Product Line, SUN VALLEY, Calif., Oct. 18 ... new,Bluetooth(R) enabled telemedicine products to their line of disease,management solutions for ... "The addition of A & D,s Bluetooth(R) enabled Blood Pressure ...
Cached Medicine News:Health News:UPMC Health Plan Launches New Product for Small Businesses 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 3Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 4Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 5Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 6Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 7Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 8Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 9Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 10Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 11Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 12Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 13Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 2Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 3Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 4Health News:XTend Medical (XDMC) Adds New Bluetooth(R) Telemedicine Products From A&D Medical 2
(Date:9/1/2015)... , Sept. 1, 2015 VolitionRx Limited ... blood-based diagnostic tests for a broad range of cancer types ... Cameron Reynolds , is scheduled to attend the 10 ... held September 9-10, 2015 in Boston, Massachusetts ... 10. Wells Fargo Securities Research conferences are ...
(Date:9/1/2015)... AMESBURY, Mass. , Sept. 1, 2015 /PRNewswire/ ... developing a next-generation infusion management system, closed on ... new investor WuXi Healthcare Ventures. Cardinal Partners, CICA, ... Partners also participated in the round. This financing ... $6B global infusion market. Leerink Partners LLC acted ...
(Date:9/1/2015)... , September 1, 2015 ... on the basis of sectors, products & services ... globally coupled with the increasing demand of advanced ... expected to propel the growth for bioinformatics market. ... information efficiently is known as bioinformatics. Decreasing cost ...
Breaking Medicine Technology:VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4
... CHICAGO, Dec. 9 Uniting the world,s most advanced ... research teams utilizing a coordinated and "wired" approach to ... innovative partnership of its kind. , Medco ... announced a collaboration that includes the State of Illinois, ...
... , CLAREMONT, Calif., Dec. 9 The U.S. ... of an orphan drug workshop series--an opportunity for biotechnology ... spend two days creating applications for orphan status designation, ... Orphan Products Development (OOPD). The first workshop is planned ...
Cached Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5FDA Launches Orphan Drug Workshop at KGI 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: